Latest Bariatric and Metabolic Surgery research

Top 4 this week

Week of 1 November 2026

1. 1

   Effect of Study Design on the Conclusions of Randomized Clinical Trials: Systematic Review and Meta-analyses on Sleeve Gastrectomy vs. Roux-en-Y Gastric Bypass on Weight Loss Outcomes after Metabolic Bariatric Surgery

   Obesity surgery · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 30 October 2026

   Across four European trials involving 975 patients, Roux-en-Y gastric bypass produced 3.6 percentage points more total weight loss at five years than sleeve gastrectomy; excess weight loss was 8.5 points higher. The findings consistently favored bypass, but whether that difference is clinically important - or the procedures count as equivalent - depends on the trial's predefined hypothesis.

2. 2

   Anatomy-Aware Effects of Biliopancreatic-Limb Length in Roux-en-Y Gastric Bypass: A Systematic Review and Meta-analysis

   Obesity surgery · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 27 October 2026

   In two trials involving 146 people, extending the biliopancreatic limb without changing the alimentary limb produced a 12-month weight-loss difference of just 0.36 percentage points, with results too uncertain to rule out smaller effects. Across the review, diabetes outcomes were sparse and varied by surgical configuration, so the isolated effect of limb length remains unclear.

3. 3

   The American Society of Metabolic and Bariatric Surgery 2022-2024 procedural volume assessment

   Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · Q1 journal · Guideline · Evidence level 1 (High) · 25 September 2026

   Among US centers reporting continuously, bariatric surgery volume fell 24.8% from 2022 to 2024; the study estimated 200,667 procedures nationwide in 2024. The decline was widespread, with 36 states reporting drops greater than 15%, and the steepest declines in states with the highest obesity rates. The data show falling use, but do not explain why.

4. 4

   Redefining surgical outcomes after metabolic and bariatric surgery: an American Society for Metabolic and Bariatric Surgery narrative literature review of composite response metrics and body composition

   Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · Q1 journal · Guideline · Evidence level 1 (High) · 5 October 2026

   This narrative review finds that weight and BMI can misclassify response to metabolic and bariatric surgery because they overlook changes in obesity-related diseases, quality of life, and body composition. Composite scores and measures of fat, lean tissue, visceral fat, and bone density offer a broader view, but research must establish how to standardize them and use them in routine care.

Paper of the day, last two weeks

• Refractory gastric leak following salvage surgery after gastrectomy: a systematic review, case report, and management algorithm

  Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · Q1 journal · SR of cohorts · Evidence level 2 (Moderate) · 14 October 2026

  A review of 10 studies and one new case included 47 patients: overall clinical success was 87.2%, and endoscopic treatment succeeded in 90.6%; repeat surgery alone succeeded in 62.5% and was associated with higher mortality. These small, nonrandomized reports favor a stepwise approach that starts with endoscopy when there is no acute peritonitis, but cannot establish which strategy is best.

• Antrectomy versus antral preservation in sleeve gastrectomy: a retrospective propensity score analysis of 675 patients

  Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · Q1 journal · Cohort · Evidence level 3 (Low) · 14 October 2026

  In a matched retrospective study, patients who had antrectomy lost 32.6% of their body weight at 12 months, versus 27.6% with antral preservation; the weight-loss advantage persisted at 3 years. Antrectomy was also linked to more leaks, bleeding, and new reflux, so the added weight loss must be weighed against these risks.

• Bariatric Surgery as a Rescue Strategy After Semaglutide or Tirzepatide

  Annals of surgery · Q1 journal · Retrospective cohort · Evidence level 3 (Low) · 3 November 2026

  Directly evaluates surgery after incretin intolerance or inadequate response

• Cardiovascular and diabetes outcomes after metabolic bariatric surgery versus obesity management medications: nationwide overlap-weighted cohort study of 379 858 patients

  The British journal of surgery · Q1 journal · Cohort · Evidence level 3 (Low) · 31 October 2026

  In a weighted nationwide cohort of adults with obesity and type 2 diabetes, kidney disease developed in 4.5% after bariatric surgery versus 8.3% after starting obesity medications over five years; eye disease, major cardiovascular events, and death were also less common. Surgery was linked to greater weight loss and blood sugar normalization at one year, but the observational design cannot prove it caused these advantages.

• Indications, Techniques, and Outcomes of Surgical Reversal Strategies after Roux-en-Y Gastric Bypass: A Systematic Review

  Obesity surgery · Q1 journal · SR of cohorts · Evidence level 2 (Moderate) · 31 October 2026

  Across 12 studies, reversal for problems such as severe low blood sugar, malnutrition, and chronic abdominal symptoms was followed by a complication in about 39% of patients and another operation in 15%; early mortality was 0.68%. Evidence was very low certainty, follow-up was often incomplete, and no best surgical technique emerged, leaving benefits and risks difficult to compare.

• Weight Loss Outcomes and Comorbidity Resolution After Roux-en-Y Gastric Bypass for Failed Primary Adjustable Gastric Banding and Sleeve Gastrectomy

  Obesity surgery · Q1 journal · Retrospective cohort · Evidence level 3 (Low) · 30 October 2026

  In this retrospective study, 83% of patients converted from sleeve gastrectomy to gastric bypass had reflux resolution at 2 years, compared with 33% converted from gastric banding. Band-to-bypass patients lost more weight in unadjusted comparisons, but the operation type was not independently linked to weight loss; the findings come from one center and need further study.

• Short- and Long-Term Control of Hypertension After Bariatric Surgery: A 10-Year Prospective Study

  MedComm · Q1 journal · Prospective cohort · Evidence level 4 (Very Low) · 29 October 2026

  In a prospective study of 248 Chinese patients with obesity and hypertension, blood pressure fell soon after bariatric surgery and remained about 15 mmHg lower systolic at follow-up; 70.8% of those assessed at 10 years had blood pressure below 140/90 mmHg. Long-term results came from smaller subsets, so durability across the full cohort remains uncertain.

• Synthesized cardiometabolic, pulmonary, and sleep outcomes after bariatric surgery in adolescents with severe obesity: A systematic review and meta-analysis

  Obesity pillars · Q1 journal · SR of cohorts · Evidence level 2 (Moderate) · 9 October 2026

  In three randomized cohorts, adolescents who had bariatric surgery had a 9.4 kg/m2 greater BMI reduction at two years than those receiving nonsurgical care; the evidence was low certainty and results varied substantially. Observational studies also reported improvement in several obesity-related conditions, but objective long-term sleep and lung outcomes were rarely measured, and nutritional deficiencies and reoperations require ongoing attention.

• Type 2 Diabetes Relapse after Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: A Systematic Review and Meta-Analysis

  Obesity surgery · Q1 journal · SR of cohorts · Evidence level 2 (Moderate) · 27 October 2026

  Across nine studies involving 24,228 patients who achieved diabetes remission after surgery, relapse was about one-third less likely after gastric bypass than after sleeve gastrectomy. The finding favors bypass for durability of remission, but most evidence was retrospective, so prospective studies are needed to confirm whether the difference reflects the procedures themselves.

• Safety and Efficiency of Robotic Versus Laparoscopic Revisional Bariatric Surgery: A Systematic Review and Meta-Analysis

  Medical sciences (Basel, Switzerland) · Q1 journal · SR of cohorts · Evidence level 2 (Moderate) · 30 September 2026

  Across six retrospective studies, robotic revisional bariatric surgery was associated with hospital stays about one day shorter than laparoscopic surgery, with no significant differences in complications, reoperations, leaks or pneumonia. The length-of-stay result was highly variable and sensitive to one large registry study, so it is a signal for further research, not proof that robotic surgery is superior.

• Metabolic disease severity after gastric bypass differs by sex, race, and ethnicity: trends using the Assessment of Obesity-related Metabolic Comorbidities scoring

  Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · Q1 journal · Unclassified · Evidence level 5 (Expert Opinion) · 2 October 2026

  In 351 patients at one US academic center, five-year patterns varied by condition: Hispanic/Latinx patients had sustained diabetes improvement, White patients had sustained improvement in cholesterol-related disease, and Black patients were the only group without significant hypertension improvement. Men had more severe hypertension before and after surgery but similar relative improvement to women; whether these differences reflect broader patient populations remains unclear.

• Hemobezoar-related jejunojejunostomy obstruction after minimally invasive Roux-en-Y gastric bypass: a systematic review

  Surgical endoscopy · Q1 journal · SR of cohorts · Evidence level 2 (Moderate) · 22 October 2026

  A review found 29 cases among 7,669 minimally invasive gastric bypass procedures; obstruction usually appeared within 72 hours and often involved signs of bleeding. Reports describe CT diagnosis and prompt surgery, with no deaths but several complications; because the evidence comes from small retrospective studies, the best management approach still needs prospective validation.